On the heels of the Dow Jones Industrial Average (DJIA) logging its worst annual performance since 1931 and the NASDAQ Composite (COMP) having its worst year since inception in 1971, it may have seemed counter intuitive to provide a bullish outlook for the biotechnology industry in 2009. Nonetheless, at the start of the year...
Read More »
Posts Tagged ‘ OGXI ’
Allos Therapeutics
ALTH
AMAG
AMAG Pharmaceuticals
American Society of Clinical Oncology
Amgen
AMGN
Amicus Therapeutics
AMLN
ASCO
BIIB
Biogen Idec
biotech
biotechnology
BMY
cancer
CELG
Celgene
CEPH
Cephalon
Cougar Biotechnology
CYCC
Cyclacel Pharmaceuticals
Dendreon
DNDN
Eli Lilly & Co
FOLD
genentech
GENZ
GlaxoSmithKline
GSK
HGSI
life sciences
LLY
OSIR
Osiris Therapeutics
PFE
Pfizer
prostate cancer
Provenge
roche
Seattle Genetics
SGEN
SNY
Soligenix
2009: Biotech’s Stealth Small Cap Rally
Molecular Insight Pharmaceuticals: In the Prostate Cancer Spotlight
Prostate cancer is the most common type of cancer found in American men, other than skin cancer. In 2009, the American Cancer Society estimates that there will be nearly 200,000 new cases of prostate cancer in the United States and that about 27,000 men will die from the disease. It is estimated that there...
Read More »
Biotech Stocks and the ASCO-effect
Investors are hoping that the spark that could reignite investor enthusiasm for biotech stocks is taking place right now. Approximately 30,000 participants are gathering from May 29-June 2, 2009, in Orlando, Florida, for the year’s largest cancer conference. Attendees of the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) will exchange...
Read More »







